Myeloma Paper of the Day, October 3rd, suggested by Robert Orlowski
Robert Orlowski shared on X:
“Myeloma Paper of the Day: Study of trends in 5-year cancer survival disparities by race and ethnicity in the US between 2002-2006 and 2015-2019 shows notable increases across groups for myeloma, but some disparities persist.”
Source: Robert Orlowski/X
Authors: Chongfa Chen, Lingdi Yin, Chunhui Lu, Guangfu Wang, Zhenyu Li, Feihu Sun, Huijuan Wang, Chenchen Li, Shangnan Dai, Nan Lv, Jishu Wei, Zipeng Lu, Feng Guo, Min Tu, Bin Xiao, Chunhua Xi, Kai Zhang, Qiang Li, Junli Wu, Wentao Gao, Xu Feng, Kuirong Jiang and Yi Miao.
Other posts featuring Robert Orlowski on OncoDaily.
Robert Orlowski, M.D., Ph.D., holds multiple positions at The University of Texas, MD Anderson Cancer Center including Chairman, Ad Interim Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics within the Division of Cancer Medicine. Additionally, he chairs the SWOG Barlogie/Salmon Myeloma Committee, which is part of the National Clinical Trials Network, dedicated to advancing new therapies and understanding the biology of myeloma.
Dr. Orlowski’s expertise lies in both clinical practice and scientific research, with a particular focus on translating laboratory discoveries into effective treatments for patients. He investigates drug resistance mechanisms in myeloma and seeks to identify predictive biomarkers for treatment response. Notably, his past contributions include leadership roles in developing proteasome inhibitors like bortezomib and carfilzomib, as well as monoclonal antibodies such as daratumumab and elotuzumab.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023